arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Puma Biotechnology Inc

PBYI Health Care Biotechnology: Pharmaceutical Preparations
$11.02
▲ +1.1% Today
as of Oct 23, 16:51 ET
Last 30 days +20.57% Sep 14 → Oct 23
$8.97 $9.59 $10.20 $10.81 $11.43 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$11.25
High
$11.50
Low
$10.91
Volume
$559,154
Avg Vol
$373,035
Mkt Cap
$506M
P/E (TTM)
37.81
Beta
—
52w High
$11.50
52w Low
$4.58
Div Yield
—
Shares Out
$51M

Recent Press Releases & News last 60 days · 8 items

Oct 22 · 20:11 PR Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Oct 20 · 12:40 Zacks
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
Oct 19 · 12:00 Zacks
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
▸ Show all 8 press releases & news Free account →

PBYI earnings at a glance

Puma Biotechnology Inc (PBYI) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of $0.06, compared with $0.17 in the same quarter last year (-65%). The options market is pricing a move of about ±8.8% after the report, a range of roughly $10.05 to $11.99 from today's $11.02. Over its last 6 reports the stock rose the next day 4 times and fell 2, moving ±12.9% on average; after the most recent report on Aug 6, 2026 it moved +9.7%. That means options currently expect less movement than PBYI has typically delivered. PBYI beat the consensus EPS estimate in 6 of its last 6 reported quarters. Implied volatility is currently 74%. The share price of $11.02 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$4.58
$12
93% of range
Avg surprise (last 6)
+192.5%
Avg reaction (last 6)
+2.8%
67% positive
Latest IV / EM
74%
EM ±8.8% · $10 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.17$-0.03$0.12$0.26$0.41 Actual $0.03Actual $0.05Actual $0.12Actual $-0.10Actual $-0.09Actual $0.41Actual $0.06Est $-0.01Actual $0.12Est $0.08Actual $0.17Est $0.07Actual $0.26Est $0.19Actual $-0.07Est $-0.17Actual $0.16Est $0.05 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-4M$18M$40M$62M$85M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Aug 6, 2026Jun/2026 $0.16 $0.05 +166.7% -58.3% +9.7% earnings
Thu May 7, 2026Mar/2026 $-0.07 $-0.17 +58.8% -216.7% +3.2% earnings
Thu Feb 26, 20268K 2026-02-26 $0.26 $0.19 +36.8% — -25.0% earnings
Thu Nov 6, 2025Sep/2025 $0.17 $0.07 +142.9% — +22.2% earnings
Thu Aug 7, 2025Jun/2025 $0.12 $0.08 +50.0% — +12.2% earnings
Thu May 8, 2025Mar/2025 $0.06 $-0.01 +700.0% — -5.2% earnings
Mon Sep 30, 2024Sep 2024 $0.41 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.09 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.10 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.12 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.05 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.03 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER $0.06$0.17 -64.7%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$57M$45M—$54M$52M$46M—$81M
Cost of revenue$12M$10M—$12M$12M$11M—$29M
Gross profit————————
Operating income$8M$-4M—$10M$7M$4M—$22M
Net income$8M$-4M—$9M$6M$3M—$20M
EPS (diluted)$0.16$-0.07—$0.17$0.12$0.06—$0.41

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$37M$36M$30M$54M$55M$63M$69M$67M
Inventory$13M$9M$6M$9M$9M$9M$9M$3M
Total current assets$145M$142M$163M$144M$137M$133M$148M$157M
Total assets$193M$193M$216M$203M$195M$196M$213M$221M
Long-term debt$0$0—$0$11M$11M$22M$33M
Total liabilities$54M$64M$86M$88M$90M$99M$121M$150M
Total equity$139M$128M$130M$115M$105M$97M$92M$71M

Implied volatility — last 90 days

14%324%634%944%1254% Jun 07 — IV 51% · EM ±7.1%Jun 08 — IV 111% · EM ±14.6%Jun 11 — IV 38% · EM ±4.1%Jun 16 — IV 201% · EM ±11.9%Jun 19 — IV 76% · EM ±16.9%Jun 22 — IV 69% · EM ±14.4%Jun 23 — IV 84% · EM ±17.1%Jun 24 — IV 114% · EM ±22.8%Jun 25 — IV 90% · EM ±17.6%Jun 26 — IV 100% · EM ±19.1%Jun 29 — IV 121% · EM ±21.4%Jun 30 — IV 136% · EM ±23.4%Jul 01 — IV 131% · EM ±21.9%Jul 02 — IV 127% · EM ±20.6%Jul 03 — IV 132% · EM ±20.6%Jul 06 — IV 158% · EM ±21.9%Jul 09 — IV 257% · EM ±30.4%Jul 10 — IV 147% · EM ±16.2%Jul 13 — IV 267% · EM ±22.3%Jul 14 — IV 810% · EM ±58.6%Jul 15 — IV 453% · EM ±26.8%Jul 16 — IV 1254% · EM ±52.4%Jul 20 — IV 136% · EM ±32.0%Jul 21 — IV 175% · EM ±40.8%Jul 22 — IV 107% · EM ±24.5%Jul 23 — IV 303% · EM ±68.0%Jul 24 — IV 51% · EM ±11.3%Jul 27 — IV 81% · EM ±16.9%Jul 28 — IV 92% · EM ±18.8%Jul 29 — IV 85% · EM ±17.0%Jul 30 — IV 94% · EM ±18.4%Jul 31 — IV 120% · EM ±23.0%Aug 03 — IV 119% · EM ±21.1%Aug 04 — IV 233% · EM ±40.1%Aug 06 — IV 270% · EM ±43.7%Aug 07 — IV 359% · EM ±56.1%Aug 10 — IV 33% · EM ±4.6%Aug 13 — IV 267% · EM ±31.6%Aug 14 — IV 354% · EM ±39.1%Aug 20 — IV 447% · EM ±18.7%Aug 24 — IV 71% · EM ±14.8%Aug 25 — IV 49% · EM ±9.9%Aug 26 — IV 44% · EM ±8.7%Aug 28 — IV 95% · EM ±18.2%Aug 31 — IV 28% · EM ±4.9%Sep 01 — IV 34% · EM ±5.9%Sep 02 — IV 40% · EM ±6.7%Sep 03 — IV 59% · EM ±9.6%Sep 04 — IV 30% · EM ±4.7%Sep 07 — IV 34% · EM ±4.7%Sep 08 — IV 107% · EM ±14.1%Sep 09 — IV 22% · EM ±2.8%Sep 10 — IV 106% · EM ±12.5%Sep 11 — IV 15% · EM ±1.6%Sep 14 — IV 314% · EM ±26.3%Sep 15 — IV 254% · EM ±18.4%Sep 21 — IV 65% · EM ±13.6%Sep 22 — IV 67% · EM ±13.7%Sep 24 — IV 76% · EM ±14.8%Sep 25 — IV 59% · EM ±11.3%Sep 28 — IV 46% · EM ±8.1%Sep 29 — IV 47% · EM ±8.1%Sep 30 — IV 66% · EM ±11.1%Oct 01 — IV 69% · EM ±11.2%Oct 02 — IV 61% · EM ±9.5%Oct 07 — IV 77% · EM ±9.7%Oct 08 — IV 74% · EM ±8.8%

Sector peers

OCS
Oculis Holding AG
$508M $7.90+0.4%
CBIO
Crescent Biopharma, Inc.
$501M $12.82-2.7%
ACRS
Aclaris Therapeutics, Inc.
$500M $3.75-1.6%
CAPR
Capricor Therapeutics, Inc.
$520M $5.93+0.8%
ARVN
Arvinas, Inc.
$487M $7.30-3.4%
EVMN
Evommune, Inc.
$472M $5.10-1.4%

PBYI earnings FAQ

When is PBYI's next earnings date?

Puma Biotechnology Inc is expected to report on November 5, 2026.

What is PBYI's expected move for earnings?

Options currently price a move of about ±8.8%, or $0.97 per share either way from $11.02.

How does PBYI stock usually react to earnings?

Across the last 6 reports the average next-day move was ±12.9%, up 4 times and down 2 times.

What EPS are analysts expecting from Puma Biotechnology Inc?

The consensus estimate is $0.06 per share, versus $0.17 a year ago.

What is PBYI's implied volatility?

PBYI's at-the-money implied volatility is about 74% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in